Fatigue and Osteopenia: Why They Share a Root Cause — and What to Do About It
In this article
- Is this you?
- Why fatigue and osteopenia are the same problem
- Mitochondria, bone turnover, and the energy link
- What drives both conditions simultaneously
- The ROOT Method applied to fatigue and osteopenia
- What we test and why
- Clinical targets with research support
- Where to start
- Frequently asked questions
A DEXA scan comes back showing reduced bone density. The GP recommends calcium supplements and weight-bearing exercise — reasonable advice, but incomplete. Because in the same appointment, the same woman mentions that she has been exhausted for two years, her sleep is broken, and she cannot get through an afternoon without feeling like she has hit a wall. The bone finding gets addressed. The fatigue gets filed under stress or perimenopause and left largely uninvestigated.
What that scenario misses is this: the fatigue and the bone loss are not two separate problems running in parallel. In a significant proportion of women in their forties and fifties, they are two expressions of the same upstream dysfunction — specifically, impaired mitochondrial energy production, nutrient deficiencies that affect both cellular metabolism and bone mineralisation, and a gut environment that is failing to absorb or process the raw materials needed for both.
Treating the bone without addressing the energy biology is like patching one end of a leaking pipe. The calcium supplements may improve the DEXA scan marginally. The fatigue continues. The underlying drivers of both accumulate.
Does this sound familiar?
This article is directly relevant if you recognise any of the following:
- You have been diagnosed with osteopenia — reduced bone density that has not yet reached osteoporosis threshold — and want to understand what is driving it beyond "getting older"
- You are experiencing persistent fatigue that worsens with exertion and does not resolve with rest
- You are in perimenopause or post-menopause and your energy, bone density, and overall resilience have declined together over a relatively short period
- You are taking calcium and vitamin D but your bone density is not improving meaningfully
- You have digestive symptoms — bloating, irregular bowel, food sensitivities — alongside fatigue and bone concerns
- Standard blood tests have come back normal but you do not feel normal
- You have a history of high stress, poor sleep, or prolonged low dietary intake of protein and minerals
These presentations share overlapping upstream biology. That is what a root-cause assessment investigates.
Why fatigue and osteopenia are the same problem
This is the part that does not get explained in a standard GP consultation because it requires a systems-level view of physiology rather than an organ-level one.
Bone is not static tissue. It is metabolically active, continuously being broken down by osteoclasts and rebuilt by osteoblasts in a process called bone remodelling. This remodelling cycle consumes significant energy — osteoblasts, the cells responsible for laying down new bone matrix, are among the most metabolically demanding cells in the body. They require a continuous ATP supply to synthesise collagen, coordinate mineralisation, and maintain their own function. Where mitochondrial energy production is impaired, osteoblast activity is reduced. The remodelling cycle shifts toward net bone loss. Osteopenia is, in part, an energy deficit expressed in skeletal tissue.
The same mitochondrial dysfunction that reduces osteoblast output produces the fatigue. The same nutrient deficiencies — B vitamins, magnesium, zinc, vitamin D — that impair cellular energy production also impair bone mineralisation. The same gut dysbiosis that reduces nutrient absorption affects both the raw material supply for bone and the mitochondrial cofactors needed for ATP production.
This is not a coincidence. It is a shared biology. And it means that a treatment approach targeting both conditions through the same upstream mechanisms will outperform one that treats each symptom in isolation.
Mitochondria, bone turnover, and the energy link
Most discussions of osteopenia focus on calcium, vitamin D, and oestrogen. These matter. But the mitochondrial dimension of bone health is underappreciated and clinically significant — particularly for women whose bone density is declining despite adequate calcium intake.
Osteoblasts are energy-intensive cells
Osteoblasts — the bone-building cells — synthesise type I collagen (the structural scaffold of bone), coordinate hydroxyapatite mineralisation onto that scaffold, and produce osteocalcin (a hormone that also regulates glucose metabolism and muscle function). Each of these processes is ATP-dependent. A 2020 review in Bone Research described mitochondrial function as "a central determinant of osteoblast differentiation and bone formation capacity." When mitochondrial ATP output falls, osteoblast differentiation is impaired — the precursor cells simply do not fully mature into functional bone-building cells.
Oxidative stress accelerates bone loss
Mitochondrial dysfunction increases reactive oxygen species (ROS) production. Elevated ROS promotes osteoclast activity — the bone-resorbing side of the remodelling equation — while simultaneously impairing osteoblast function. The net effect is a remodelling cycle that erodes bone faster than it rebuilds it. This is one mechanism by which chronic oxidative stress from poor diet, high psychological stress, environmental toxin exposure, and age-related mitochondrial decline accelerates bone loss independent of oestrogen status.
The oestrogen-mitochondria interaction
Oestrogen directly supports mitochondrial function in several ways: it upregulates antioxidant enzyme expression in mitochondria, supports mitochondrial biogenesis via oestrogen receptor beta (ERβ), and reduces ROS production in bone cells specifically. When oestrogen declines in perimenopause and menopause, this mitochondrial protection is withdrawn simultaneously. The result is that the two primary bone-protective mechanisms — oestrogen signalling and mitochondrial efficiency — decline together, producing a compounding effect on bone loss that is faster and more significant than either factor alone would produce.
This is why the perimenopausal years are not just a hormonal transition but a metabolic one — and why addressing mitochondrial function is not a peripheral concern in bone health management for women in their forties and fifties. It is central to it.
Calcium feeds the bone. Energy builds it. Without adequate mitochondrial ATP production, osteoblasts cannot do their job regardless of how much calcium is circulating. This is why women can have normal calcium levels and still lose bone density — the building machinery is underpowered.
What drives fatigue and osteopenia simultaneously
These are the clinical drivers I investigate when fatigue and bone loss present together. In most women, several are active simultaneously:
Mitochondrial dysfunction
Impaired electron transport chain function reduces ATP output in all energy-demanding tissues simultaneously — including skeletal muscle (producing fatigue) and osteoblasts (reducing bone formation). The same ETC impairment drives both symptoms through the same mechanism.
Clinical note: Elevated lactate, disordered Krebs cycle intermediates, and low CoQ10 functional markers on the Organic Acids Test are the primary indicators. Standard blood tests do not capture this.
Nutrient deficiencies — overlapping requirements
Magnesium, zinc, B vitamins (particularly B1, B2, B6, B12), vitamin D, and vitamin K2 are all required for both mitochondrial energy production and bone mineralisation. A deficiency in any of these affects both systems. Magnesium is particularly critical — it is a cofactor for over 300 enzymes including ATP synthase, and it is required for vitamin D activation and calcium metabolism in bone.
Clinical note: Australian dietary surveys consistently show inadequate magnesium intake across adult women. Serum magnesium is a late and insensitive marker of deficiency — red cell magnesium is the more clinically relevant test.
Gut malabsorption and dysbiosis
The gut is the delivery system for every nutrient involved in both energy production and bone building. Intestinal permeability, dysbiosis, and reduced digestive enzyme or stomach acid output all reduce the bioavailability of calcium, magnesium, zinc, vitamin D, and protein — the raw materials for bone — as well as the B vitamin and mineral cofactors that run the mitochondrial electron transport chain.
Clinical note: Fungal overgrowth (Candida) and oxalate accumulation are two specific gut-related factors that both impair mitochondrial function (via toxin production) and reduce calcium availability for bone (via oxalate-calcium binding). Both show up on the Organic Acids Test.
HPA axis dysregulation and cortisol excess
Chronic cortisol elevation from sustained psychological or physiological stress directly inhibits osteoblast activity and accelerates osteoclast-mediated bone resorption. It also depletes progesterone (via pregnenolone steal), increases mitochondrial ROS production, disrupts sleep architecture, and impairs thyroid function — all of which compound both fatigue and bone loss.
Clinical note: Women in high-stress periods who report their fatigue and bone density decline starting around the same time frequently have a cortisol pattern story behind both. A salivary cortisol panel maps this directly.
Oestrogen and progesterone decline
Oestrogen maintains bone density by suppressing osteoclast activity and supporting osteoblast survival. Progesterone directly stimulates new bone formation via progesterone receptors on osteoblasts. Both decline in perimenopause, often unevenly — progesterone typically drops first, creating a period of relative oestrogen dominance followed by a more complete hormonal withdrawal. The timing of bone loss acceleration frequently tracks the hormonal pattern closely.
Clinical note: The standard bone density conversation focuses on oestrogen. Progesterone's direct role in bone formation is less discussed but clinically significant — particularly for women with anovulatory cycles or significant luteal phase deficiency in the perimenopausal years.
Low protein intake
Collagen is the structural scaffold of bone — approximately 90% of the organic bone matrix is type I collagen. Collagen synthesis requires adequate dietary protein, vitamin C, zinc, and copper. Chronically low protein intake — common in women who have restricted calories over years — impairs collagen production directly, reducing bone matrix quality independent of mineralisation. Low protein also reduces IGF-1, a key anabolic signal for both bone formation and muscle maintenance.
Clinical note: Many women with osteopenia have a history of caloric restriction or low protein intake. Bone density improvement is consistently stronger in studies combining calcium and vitamin D with adequate protein than in studies using mineral supplementation alone.
Thyroid dysfunction
Both hypothyroidism and subclinical hypothyroidism reduce mitochondrial biogenesis and impair cellular energy production — producing fatigue. Thyroid hormones also regulate the rate of bone remodelling. Hypothyroidism slows the entire remodelling cycle, which over time reduces bone quality. Hyperthyroidism accelerates remodelling in a way that favours net bone loss. Either direction of thyroid dysfunction affects bone, via different mechanisms.
Clinical note: A full thyroid panel — TSH, free T3, free T4, and thyroid antibodies — is essential in any woman presenting with unexplained fatigue and declining bone density. TSH alone misses a significant proportion of clinically relevant thyroid dysfunction.
Fatigue and bone density concerns that haven't been fully explained?
A 20-minute discovery call can clarify whether a functional medicine assessment makes sense for your presentation. No referral required.
Book a free discovery callThe ROOT Method applied to fatigue and osteopenia
The standard approach to osteopenia is supplement-driven: calcium, vitamin D, maybe bisphosphonate medication if density is low enough. The standard approach to fatigue is either investigation for anaemia or thyroid dysfunction (reasonable) or a recommendation to sleep more and manage stress (incomplete). Neither approach asks what is upstream of both.
The ROOT Method™: Applied to Fatigue and Osteopenia
The ROOT Method works through four investigative layers. For fatigue and osteopenia presenting together, each layer has specific clinical content:
- R — Root Cause Identification: Is the primary driver mitochondrial dysfunction, nutrient deficiency, gut malabsorption, HPA axis dysregulation, hormonal decline, or some combination? The overlap between fatigue and bone loss suggests shared upstream biology — the investigation identifies which mechanisms are active and in what proportion. This changes the entire treatment approach.
- O — Optimise Function: Restoring mitochondrial energy production through targeted cofactor support (CoQ10, B vitamins, magnesium, carnitine); correcting identified nutrient deficiencies with therapeutic doses rather than RDI-level supplementation; supporting osteoblast activity with vitamin K2, hydroxyapatite, and protein; addressing HPA axis dysfunction to reduce cortisol-mediated bone resorption.
- O — Ongoing Monitoring: Using the Organic Acids Test and salivary hormone panels at baseline and at three months to track objective change in mitochondrial function, nutrient status, and hormonal patterns — alongside DEXA scan findings at appropriate intervals. Symptom improvement matters, but objective markers tell us whether the underlying mechanisms are actually changing.
- T — Total Health Integration: Diet quality and protein adequacy, gut health restoration, sleep architecture, stress physiology, weight-bearing exercise prescription, and hormonal support where indicated — addressed as an integrated system rather than separate interventions. The body does not manage bone and energy in separate departments.
What we test and why
Standard investigations for both fatigue and osteopenia frequently leave the most clinically relevant mechanisms untested. Here is what a functional medicine workup adds:
Organic Acids Test (OAT)
The OAT is the single most informative test for the shared biology of fatigue and osteopenia. For this presentation, the key markers are Krebs cycle intermediates (assessing mitochondrial energy flux), CoQ10 functional markers, B vitamin functional status, oxalate levels (elevated oxalates bind calcium and impair mitochondrial function — a direct dual-pathway driver), fungal and bacterial dysbiosis markers, and oxidative stress indicators. In women with both fatigue and declining bone density, the OAT frequently reveals the specific mechanisms that are active — and that standard pathology has not captured.
Adrenal Cortex Female Hormone Saliva Panel
A four-point salivary collection measuring oestradiol, progesterone, the oestradiol:progesterone ratio, DHEA-S, and diurnal cortisol. For bone health specifically, the oestradiol and progesterone levels directly inform bone remodelling status. The cortisol pattern maps the HPA axis dysregulation that drives osteoclast activity and progesterone depletion. DHEA-S is an adrenal androgen that converts to oestrogen peripherally — its status is clinically relevant in post-menopausal women where it becomes a more significant source of circulating oestrogen. This panel gives the hormonal bone picture in a way that a single serum oestradiol cannot.
Comprehensive Blood Panel
Beyond standard pathology: full thyroid panel (TSH, free T3, free T4, TPO antibodies), red cell magnesium, serum zinc, 25-OH vitamin D (aiming for a functional range of 100-150 nmol/L rather than the laboratory lower limit of 50 nmol/L), ferritin, vitamin B12 (as active B12/holotranscobalamin where possible), fasting insulin and HOMA-IR, high-sensitivity CRP, and a full bone markers panel where indicated (osteocalcin, CTX as a bone resorption marker, P1NP as a bone formation marker). These markers tell us the rate of bone turnover and the direction it is moving — information a DEXA scan alone does not provide.
Fatigue Workup
For women where fatigue is the primary presenting complaint alongside the bone findings, the fatigue workup and the bone biology workup overlap substantially — because the upstream drivers are shared. I assess adrenal function, mitochondrial metabolic markers, gut function, inflammatory load, and nutrient status as a single integrated investigation rather than separate referrals. The separation of "bone specialist" and "fatigue clinic" is an administrative distinction, not a biological one.
Clinical targets: what the research supports
CoQ10 for mitochondrial energy and bone
CoQ10 is a structural component of the mitochondrial electron transport chain and a potent lipid-soluble antioxidant. Its relevance to bone is direct: CoQ10 deficiency reduces osteoblast ATP production and increases oxidative stress in bone tissue. Several human trials have shown that CoQ10 supplementation improves markers of bone formation (osteocalcin, P1NP) and reduces markers of bone resorption (CTX). A 2015 study in the Journal of Clinical Biochemistry and Nutrition found that CoQ10 supplementation alongside standard calcium and vitamin D produced significantly greater improvements in bone turnover markers than calcium and vitamin D alone. The energy and the bone benefit are mechanistically linked — CoQ10 supports both through the same mitochondrial pathway.
Vitamin K2 (MK-7) — directing calcium to bone
Vitamin K2 activates osteocalcin — the protein that binds calcium into the bone matrix — via carboxylation. Without adequate K2, osteocalcin remains undercarboxylated and cannot perform this function effectively. Calcium circulates but does not mineralise bone properly, and may instead deposit in arterial walls. The MK-7 form of vitamin K2 has superior bioavailability and a longer half-life than MK-4. A three-year randomised controlled trial published in Osteoporosis International (2013) found that MK-7 supplementation at 180mcg daily significantly reduced the rate of bone loss in post-menopausal women compared to placebo. Vitamin K2 is consistently underrepresented in standard osteopenia management despite a strong mechanistic rationale and growing clinical evidence.
Magnesium — the overlooked bone mineral
Approximately 60% of the body's magnesium is stored in bone. Magnesium is required for vitamin D activation (the conversion of 25-OH vitamin D to its active 1,25-dihydroxy form requires a magnesium-dependent enzyme), for calcium metabolism in bone tissue, and for ATP synthase function in osteoblasts. Population data in Australia consistently shows inadequate magnesium intake in adult women. The form matters: magnesium glycinate and magnesium malate have superior bioavailability and tolerability over magnesium oxide, which is the most common form in cheap supplements and is poorly absorbed.
Active B vitamins and methylation support
B12, folate (as 5-MTHF), B6 (as P5P), and B2 are required for the methylation cycle that controls homocysteine. Elevated homocysteine is an independent risk factor for fracture — it directly interferes with collagen cross-linking in bone matrix, reducing bone quality and strength even when density appears adequate on DEXA. B vitamins also support mitochondrial energy production as ETC cofactors. In women with MTHFR variants — common in the Australian population — active methylated forms of folate and B12 are required rather than the standard synthetic forms found in most supplements.
Hydroxyapatite versus calcium carbonate
Microcrystalline hydroxyapatite (MCHA) is the naturally occurring mineral form of calcium found in bone, providing both calcium and phosphate in the correct ratio along with trace minerals including zinc, magnesium, and boron. Multiple comparative trials have shown MCHA produces superior improvements in bone density over calcium carbonate — partly because it delivers the mineral in the bioavailable form already used by bone tissue, and partly because it supplies the trace minerals that calcium carbonate supplements omit. For women who are taking calcium supplements with limited benefit, the form is worth revisiting.
Exercise — the non-negotiable input
Weight-bearing and resistance exercise is the primary mechanical stimulus for bone formation. Mechanical loading activates osteocytes (bone sensor cells), which signal osteoblasts to increase bone matrix production. No nutritional protocol substitutes for this signal. Progressive resistance training two to three times per week, combined with impact-loading activities (walking, jogging, dancing) on alternate days, produces the strongest combined mechanical stimulus for bone. Exercise also improves mitochondrial biogenesis via PGC-1α, directly addressing the energy side of the equation. In perimenopausal and post-menopausal women, resistance training is the single most evidence-supported intervention for both bone density and fatigue.
Progesterone support where indicated
Progesterone has direct bone-building effects via progesterone receptors on osteoblasts. Dr Jerilynn Prior's research, including the Canadian CEMCOR cohort studies, has documented that progesterone deficiency — common in perimenopausal women with anovulatory cycles — is a significant contributor to the bone loss that begins before oestrogen levels drop meaningfully. Where the salivary hormone panel reveals low progesterone relative to oestradiol, targeted progesterone support is a direct bone intervention, not just a hormonal one. Vitex agnus-castus (chaste tree) supports progesterone production in perimenopausal women with residual ovarian function. Bioidentical progesterone is a clinical option where indicated.
Where to start if this resonates
If you have been diagnosed with osteopenia and are also carrying persistent fatigue, the most useful reframe is this: you do not have two separate problems. You have one metabolic picture with two visible expressions. Addressing them separately — calcium for the bones, lifestyle advice for the fatigue — will produce partial results at best.
The first honest question is whether the investigation you have had actually tested the right things. A DEXA scan measures bone density at a point in time. It does not tell you the rate of bone turnover, the hormonal drivers of bone loss, the mitochondrial energy status of your osteoblasts, the nutrient cofactor availability for bone matrix synthesis, or the gut function affecting mineral absorption. Standard blood tests catch anaemia and thyroid dysfunction — important — but miss the functional nutrient deficiencies and mitochondrial stress markers that are frequently the most clinically relevant findings in this presentation.
The second question is whether any of the drivers described above apply to your situation. Chronic high stress. Years of restricted eating or low protein intake. Perimenopausal hormonal changes. Digestive symptoms that have been managed rather than investigated. These are not incidental details — they are direct inputs into both bone biology and cellular energy production.
The third is getting a clinical assessment that holds both presentations together as one system rather than referring them to separate specialists. The questions that matter — about mitochondrial function, nutrient status, hormonal patterns, gut health — require a functional medicine framework and a different set of tests to answer properly.
Working with me at Vital Health and Natural Medicine
I see patients at my Kealba clinic (195A Sunshine Ave, Kealba VIC 3021) and via telehealth nationally. Initial consultation $197, follow-up $130. No referral required.
For women presenting with fatigue alongside osteopenia or declining bone density, my initial workup centres on the Organic Acids Test, the salivary hormone panel, and a targeted blood panel covering thyroid, nutrient status, bone turnover markers, and inflammatory load. Where gut symptoms are present, a GI Microbiome Map is added.
I am not offering to replace your GP or endocrinologist. I am offering to investigate what they have not yet measured — and to treat both presentations as the single metabolic problem they are.
Ready to address the root cause of your fatigue and bone health concerns?
Book a free 20-minute discovery call to discuss your presentation and whether a functional medicine assessment makes sense for you.
Book your free discovery callFrequently asked questions
Can fatigue and osteopenia really have the same cause?
Yes — and this is more common than the standard clinical framework suggests. Mitochondrial dysfunction reduces ATP production in all energy-demanding tissues, including both skeletal muscle (producing fatigue) and osteoblasts (reducing bone formation capacity). Nutrient deficiencies that impair the electron transport chain — magnesium, B vitamins, CoQ10, zinc — simultaneously impair bone mineralisation because the same cofactors are required for both. Gut malabsorption reduces the supply of nutrients to both systems at once. When fatigue and declining bone density are appearing together in a perimenopausal woman, a shared upstream cause is the most likely explanation.
Is calcium supplementation enough to treat osteopenia?
Usually not on its own. Calcium is one raw material in bone, but bone formation also requires collagen synthesis (protein, vitamin C, zinc, copper), mineralisation signalling (vitamin K2, vitamin D, magnesium), osteoblast energy production (mitochondrial ATP), and an absence of excessive bone resorption (driven by cortisol, ROS, oestrogen and progesterone deficiency). Calcium without the supporting co-factors and without addressing the drivers of bone loss frequently produces limited improvement on DEXA. The form of calcium also matters — microcrystalline hydroxyapatite has consistently outperformed calcium carbonate in comparative trials.
What does the Organic Acids Test show for bone and fatigue?
The OAT provides a metabolic snapshot that captures mitochondrial energy flux (Krebs cycle intermediates, ETC function markers), B vitamin functional status, CoQ10 adequacy, oxidative stress burden, oxalate levels (elevated oxalates bind calcium and impair mitochondrial function directly), and gut dysbiosis including fungal overgrowth. For women with both fatigue and osteopenia, the OAT frequently reveals the specific mechanisms that standard pathology has missed — and provides a baseline against which treatment response can be tracked at three months.
Does progesterone affect bone density?
Yes — progesterone has direct bone-forming effects via progesterone receptors on osteoblasts. This is separate from oestrogen's role in suppressing bone resorption. Research by Dr Jerilynn Prior and the CEMCOR group has documented that progesterone deficiency — common in perimenopausal women with anovulatory cycles before oestrogen levels drop significantly — is a clinically meaningful contributor to early bone loss. The standard bone health conversation focuses almost entirely on oestrogen; progesterone's contribution to bone formation is underemphasised in both mainstream and natural medicine practice.
Why is vitamin K2 important for bone health?
Vitamin K2 activates osteocalcin — the protein that binds calcium into the bone matrix — via a process called carboxylation. Without adequate K2, osteocalcin remains inactive, calcium is poorly incorporated into bone, and may instead deposit in soft tissues including arterial walls. K2 is not the same as vitamin K1 (which is involved in blood clotting). The MK-7 form of K2 has superior bioavailability and duration of action. A three-year RCT showed MK-7 at 180mcg daily significantly reduced the rate of bone loss in post-menopausal women. Despite this, vitamin K2 is absent from most standard osteopenia protocols.
How long does it take to see improvement in bone density?
Bone remodelling cycles take three to six months to complete, and meaningful improvements in DEXA scan findings typically take twelve to twenty-four months of consistent intervention to appear. However, improvement in bone turnover markers — osteocalcin (formation) and CTX (resorption) — can be detected on blood testing within three to six months and provides earlier evidence that the remodelling cycle is shifting in the right direction. Energy and fatigue improvement generally precedes bone density changes, which is a useful early indicator that the treatment approach is working.
Do I need a referral to see a naturopath for fatigue and osteopenia?
No referral is required at Vital Health and Natural Medicine. Initial consultations are $197 and available in-clinic at Kealba, Melbourne, or via telehealth nationally across Australia. A free 20-minute discovery call is available for women who want to discuss their presentation before booking a full consultation.
Related reading: Women's hormonal health at Vital Health | Chronic fatigue and mitochondrial function | Organic Acids Test | Hormone Saliva Testing | Book a discovery call
Disclaimer: This article is for educational purposes and does not constitute medical advice. If you are experiencing fatigue or have been diagnosed with osteopenia, please seek assessment from a qualified health professional. This content is prepared by Domenic Pisanelli, naturopath and functional medicine practitioner (ATMS registered), at Vital Health and Natural Medicine, 195A Sunshine Ave, Kealba VIC 3021. Phone: 03 9382 9790.
